2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal|2022Cited by 2.7k
Myocarditis in Patients Treated With Immune Checkpoint InhibitorsSyed Mahmood, Tomas G. Neilan, Sachin Shah et al.|Journal of the American College of Cardiology|2018Cited by 1.5k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology SocietyAlexander R. Lyon, Teresa López‐Fernández, Daniel J. Lenihan et al.|European Journal of Heart Failure|2020Cited by 767
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementJoerg Herrmann, Peter Valent, Daniel J. Lenihan et al.|European Heart Journal|2021Cited by 589
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)Alexander R. Lyon, Julia Grapsa, Teresa López‐Fernández et al.|European Heart Journal - Cardiovascular Imaging|2022Cited by 486